[ad_1]
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Perrigo (NYSE:PRGO – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Insider and Institutional Ownership
95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Amylyx Pharmaceuticals has a beta of -0.6, meaning that its share price is 160% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.
Dividends
Amylyx Pharmaceuticals pays an annual dividend of $1.02 per share and has a dividend yield of 19.0%. Perrigo pays an annual dividend of $1.16 per share and has a dividend yield of 4.3%. Amylyx Pharmaceuticals pays out -32.7% of its earnings in the form of a dividend. Perrigo pays out -88.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Perrigo has increased its dividend for 23 consecutive years.
Profitability
This table compares Amylyx Pharmaceuticals and Perrigo’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -36.97% | -29.61% |
| Perrigo | -3.64% | 7.38% | 3.18% |
Analyst Ratings
This is a breakdown of recent recommendations for Amylyx Pharmaceuticals and Perrigo, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 0 | 1 | 5 | 2 | 3.13 |
| Perrigo | 0 | 3 | 1 | 0 | 2.25 |
Amylyx Pharmaceuticals currently has a consensus price target of $9.83, suggesting a potential upside of 83.46%. Perrigo has a consensus price target of $33.00, suggesting a potential upside of 21.32%. Given Amylyx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Amylyx Pharmaceuticals is more favorable than Perrigo.
Earnings and Valuation
This table compares Amylyx Pharmaceuticals and Perrigo”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | -$1.27 million | -375.63 | $49.27 million | ($3.11) | -1.72 |
| Perrigo | $4.34 billion | 0.86 | -$12.70 million | ($1.31) | -20.76 |
Amylyx Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company’s products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Amylyx Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link